Investor Relations

Investor Relations

Invest in Quadrant Biosciences

We’ve joined the fight against COVID-19, and you can help.

Invest in Quadrant Biosciences

We’ve joined the fight against COVID-19, and you can help.

“Our goal is to develop saliva-based diagnostic tests that maximize the potential for interventions to improve abilities, outcomes, and quality of life.”

-Rich Uhlig, Founder & CEO

The Clarifi® diagnostic platform leverages new discoveries in epigenetics and the microbiome to provide first of its kind diagnostic solutions to many of today’s critical health care challenges.  Developed in medical research labs at SUNY Upstate Medical University and Penn State College of Medicine, Clarifi ASD® recently launched commercially in the US.  It is the first of its kind saliva test for autism spectrum disorder.  Quadrant is currently involved in three COVID-19 related projects with SUNY Upstate Medical University.

Why invest in Quadrant Biosciences?

Global leaders in the development of saliva-based epigenetic diagnostics

We develop saliva-based, RNA diagnostic solutions for autism spectrum disorder, Parkinson’s disease, concussion injury, and surveillance solutions for COVID-19.  We recently launched Clarifi ASD®, the world’s first saliva test for autism.

Comprehensive COVID-19 testing projects

In response to the COVID-19 pandemic, we leveraged our expertise in RNA analysis and became actively engaged in several major COVID-19 testing projects that involve individual testing, group (pooled) surveillance testing, and municipal wastewater surveillance.

An experienced management team

We have assembled an experienced management team led by former Morgan Stanley Bank CEO Rich Uhlig, as well as an expert medical advisory board comprised of recognized leaders in the areas of autism and epigenetic research to confidently guide us into the future.

Quadrant Biosciences company overview

As seen on

News room

OraSure's OMNIgene® ORAL Collection Device Receives FDA Emergency Use Authorization for SARS CoV-2

GlobeNewswire | October 2020

OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announces its DNA Genotek subsidiary has received Emergency Use Authorization (EUA) from the U.S. Fooda and Drug Administration (FDA) for the use of DNA Genotek’s OMNIgene® ORAL (OM-505, OME-505) saliva collection and stabilization device in COVID-19 testing.

Upstate Medical Gets FDA Approval for Wider Use of its Saliva Swab COVID-19 Test

CNY Business Journal | October 2020

The COVID-19 test that’s been used for extensive testing of SUNY students now has the go-ahead for use on a wider scale.

Coronavirus smoke detector launched in Syracuse put brakes on SUNY Oneonta outbreak

Syracuse.com | September 2020

A sewage testing process developed in Syracuse helped SUNY Oneonta put the brakes on a coronavirus outbreak in August that infected more than 700 students.

OraSure's ORAcollect® RNA Devise Included in the EUA Granted to Quadrant Biosciences Inc. for COVID-19 Test

Biospace | September 2020

OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its ORAcollect® RNA (OR-100) saliva collectin device has been included in the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) granted to Quadrant Biosciences Inc. for a COVID-19 laboratory test.

Governor Cuomo and Chancellor Malatras Announce FDA Approval for COVID-19 Saliva Swab Test

NYS Governor’s Office | September 2020

Governor Andre M. Cuomo and State University of New York Chancellor Jim Malatras today announced that the individual saliva swab diagnostic test for COVID-19 developed by SUNY Upstate Medica and Quadrant Biosciences has been granted emergency use authorization by the U.S. Food and Drug Administration.

SUNY may implement biweekly testing to stem campus COVID-10 outbreaks

NY Post | September 2020

Students attending the State University of New York’s 64 campuses could be tested for the coronavirus as often as every two weeks to prevent outbreaks of the killer bug, officials said Friday.

Saliva test for COVID-19 approved by NY Dept. of Health

WHAM 13 | September 2020

A rapid test designed to use a patient’s saliva to diagnose cases of COVID-19 is now available for use on SUNY campuses.

Governor Cuomo and Chancellor Malatras Announce FDA Approval for COVID-19 Saliva Swab Test

NYS Governor’s Office | September 2020

Governor Andre M. Cuomo and State University of New York Chancellor Jim Malatras today announced that the individual saliva swab diagnostic test for COVID-19 developed by SUNY Upstate Medica and Quadrant Biosciences has been granted emergency use authorization by the U.S. Food and Drug Administration.

Governor Cuomo Announces New Testing Initiatives to Improve COVID-19 Detection & Control Across New York State

NYS Governor’s Office | August 2020

Governor Andrew M. Cuomo today announced a series of new initiatives related to COVID-19 testing that will improve New York State’s ability to detect and control the virus in communities across the state.

University Scientists Selected to Implement COVID-19 Early Warning System in Upstate New York

SUNY ESF| August 2020

Game-changing approach will help inform decision-making, protect public health in Albany, Buffalo and Syracuse

New York State partners with Arcadis to pilot early detection of COVID-19 in wastewater

GlobeNewswire | August 2020

Game-changing approach will help inform decision-making, protect public health in upstate communities.

Groundbreaking autism test developed in CNY would diagnose children through saliva
CNY Central | December 2019

Traditionally, children who are thought to have autism are put through a series of practical tests. About one in 59 children are diagnosed with Autism Spectrum Disorder in the United States, according to the CDC.

Saliva test for autism hits market; Syracuse research could lead to faster help for kids
Syracuse | December 2019

A saliva test designed to quickly diagnose autism in toddlers has hit the market after seven years of research at SUNY Upstate Medical University and Penn State.

Microbes in Saliva May Offer Way of Detecting and Understanding Early Stages of Parkinson’s, Study Says
Parkinsons News Today | July 2019

A saliva test to detect oral microbes may offer an accurate way of detecting Parkinson’s in its early stages and further understanding of the disease, a study reports.

Quadrant Biosciences Recognized as New York Technology Business of the Year
Market Watch | May 2019

Quadrant Biosciences Inc. has been awarded the Technology Business of the Year by the New York State Small Business Development Center (SBDC).

Study finds correlation between specific epigenetic molecules and autism traits
BioSpace | April 2019

Scientists have discovered certain molecules in the saliva that not only differentiate children with autism spectrum disorder (ASD), but appear to correlate with specific autism traits.

Press releases

Saliva may hold the key to concussion diagnosis and management - October 20, 2020
  Simple saliva test also may predict nature and duration of concussion symptoms

A simple saliva swab may hold the key to diagnosing and managing mild traumatic brain injury (i.e., concussions), according to a study recently published in the journal Clinical and Translational Medicine.

Quadrant Biosciences Receives FDA Emergency Authorization for New COVID-19 Saliva Test - September 23, 2020
  Quadrant Biosciences Inc, announced today that it has received an Emergency Use Authorization from the FDA.

The Clarifi COVID-19 Test, developed in partnership with SUNY Upstate Medical University, leverages Quadrant Biosciences’ established expertise in RNA-based diagnostics.

Quadrant Biosciences Wins $2.3M NIH Grant to Develop Saliva Test for Concussion - September 15, 2020
  Quadrant Biosciences has received a $2.3 million grant from the National Institutes of Health to develop its saliva-based microRNA diagnostic test for concussions in children and adolescents.

Quadrant has been working with researchers from Penn State University and SUNY Upstate Medical University on saliva-based biomarkers of various neurological conditions.

Renowned autism researcher Dr. Thomas Frazier joins Quadrant Biosciences Clinical Advisory Board - June 30, 2020
  Dr. Frazier will help guide research and clinical acceptance of the new Clarifi autism saliva test.

Dr. Frazier, a Professor of Psychology at John Carroll University, is one of the leading researchers in the field of autism.  Before joining the faculty at John Carroll, he was the Chief Science Officer for Autism Speaks, the largest autism advocacy organization in the United States.

Quadrant Biosciences Receives CPT® Proprietary Laboratory Analyses Code from the American Medical Association - April 21, 2020
Company That just Released World’s First Saliva Test for Autism Opens Up Investment Opportunity to the Public -
March 31, 2020
Quadrant Biosciences Inc, a leading developer of epigenetic diagnostic solutions, including the world’s first saliva test for autism, announced that it is now offering common shares of the company (at a price of $3/share, with a minimum investment of $300) through equity crowdfunding platform Wefunder.

The Reg A plus campaign is Quadrant’s first offering of common shares to the public — the company has previously raised over $32 million through private sales of its common shares to accredited investors only.

Quadrant Biosciences Launches First Ever Epigenetic Saliva Test for Autism - December 4, 2019
New Research shows link between Parkinson's disease and the microbiome - July 01, 2019
The oral microbiome may yield early biomarker for the disease.

A simple saliva swab may provide an accurate way of detecting Parkinson’s disease in its earliest stages, according to a study just published in the journal Plos One.

Quadrant Biosciences Recognized as New York Technology Business of the Year - May 7, 2019
Company’s Innovative Technology Recognized for its Social and Economic Impact

Quadrant Biosciences Inc. has been awarded the Technology Business of the Year by the New York State Small Business Development Center (SBDC).

Quadrant Biosciences Partners with Leading Edge Genomic Testing Company Admera Health - August 08, 2018
Rising companies in diagnostic space form strategic partnership.

Quadrant Biosciences Inc., an emerging life science company based in Syracuse, New York, is pleased to announce its strategic partnership with Admera Health, an advanced molecular diagnostics company headquartered in South Plainfield, NJ.

Wall Street Veteran Peter Cohen joins Quadrant Biosciences Board of Directors - April 24, 2018
Quadrant Biosciences Inc., a Syracuse, New York-based Life Science company, announced today that Wall Street veteran Peter Cohen will be joining its Board of Directors.

Mr. Cohen is currently Chairman of the Board of Cowen Inc., a well-known diversified financial services firm. Quadrant Bioscience, which focuses on the development of functional assessment and epigenetic biomarkers for various neurological conditions…

Published research

Diagnosing mild traumatic brain injury using saliva RNA compared to cognitive and balance testing
Validation of a Salivary RNA Test for Childhood Autism Spectrum Disorder
Oral microbiota and autism spectrum disorder (ASD)
The oral microbiome of early stage Parkinson’s disease and its relationship with functional measures of motor and non-motor function
Parent Perspectives Towards Genetic and Epigenetic Testing for Autism Spectrum Disorder
Saliva MicroRNA Differentiates Children With Autism From Peers With Typical and Atypical Development
A Review of MicroRNA Biomarkers in Traumatic Brain Injury
Comparison of serum and saliva miRNAs for identification and characterization of mTBI in adult mixed martial arts fighters

What do our investors have to say about us?

Meet the team

We have assembled a seasoned management team, as well as an experienced clinical advisory board comprising recognized leaders in the areas of autism and epigenetic research to confidently guide us into the future.

Our Board of Directors is composed of individuals with substantial knowledge and experience in the areas of finance, law, medicine, operations, intellectual property, and sales.

Learn more about investing with us